Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLS-5310 Booster in Prior SARS-CoV-2 Vaccinated Subjects
NCT05182567Phase 1Unknown
- Sponsor
- GeneOne Life Science, Inc.
- Start
- May 2022
- Primary completion
- Jan 2023
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 2
01
Overview
Phase 1, randomised, single-blind trial of GLS-5310 in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by GeneOne Life Science, Inc. Primary endpoints: Incidence of adverse events at 48 weeks and Antibody responses after a single dose of vaccine at 48 weeks. Status: unknown.
02
Drugs
GLS-5310
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05182567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05182567.